Accelerate Diagnostics

Accelerate Diagnostics Days Payable Outstanding

Delisted

The Days Payable Outstanding (DPO) of Accelerate Diagnostics (AXDX) as of Nov 10, 2026 is 196.58. In the previous year, Days Payable Outstanding (DPO) was 184.09 — a change of 6.78% (higher).

Days Payable Outstanding

196.58

YoY

6.78%

Last updated:

Days Payable Outstanding (DPO) of Accelerate Diagnostics is 2024 196.58 . Days Payable Outstanding (DPO) of Accelerate Diagnostics was 2023 184.09 . It decreases by 6.78% higher compared to the previous year.

The Accelerate Diagnostics Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2017
757.68 USD
Jan 1, 2018
151.41 USD
Jan 1, 2019
175.23 USD
Jan 1, 2020
70.21 USD
Jan 1, 2021
59.51 USD
Jan 1, 2022
173.87 USD
Jan 1, 2023
184.09 USD
Jan 1, 2024
196.58 USD
The Accelerate Diagnostics Days Payable Outstanding history
YEARDays Payable OutstandingYoY
196.58+6.78%
184.09+5.88%
173.87+192.17%
59.51-15.25%
70.21-59.93%
175.23+15.74%
151.41-80.02%
757.68+13,375.44%
5.62-74.22%
21.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

Days Payable Outstanding (DPO) of Accelerate Diagnostics is 196.58 in 2024.

Days Payable Outstanding (DPO) of Accelerate Diagnostics changed from 184.09 to 196.58, representing a 6.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Accelerate Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics